Synageva BioPharma Corp Trading Down 4% After Analyst Downgrade (GEVA)
Synageva BioPharma Corp (NASDAQ:GEVA)’s share price fell 4% during mid-day trading on Friday after Nomura lowered their price target on the stock from $144.00 to $140.00, Analyst Ratings Net reports. Nomura currently has a buy rating on the stock. Synageva BioPharma Corp traded as low as $86.27 and last traded at $87.06, with a volume of 86,210 shares changing hands. The stock had previously closed at $90.73.
A number of other analysts have also recently weighed in on GEVA. Analysts at Janney Montgomery Scott upgraded shares of Synageva BioPharma Corp from a “neutral” rating to a “buy” rating in a research note on Thursday. Separately, analysts at Wedbush upgraded shares of Synageva BioPharma Corp from a “neutral” rating to an “outperform” rating in a research note on Tuesday, April 8th. They now have a $93.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at Morgan Stanley reiterated an “overweight” rating on shares of Synageva BioPharma Corp in a research note on Tuesday, April 1st. They now have a $118.00 price target on the stock. Eight research analysts have rated the stock with a buy rating, The company has an average rating of “Buy” and an average price target of $110.00.
The stock has a 50-day moving average of $83.91 and a 200-day moving average of $77.38. The company’s market cap is $2.641 billion.
Synageva BioPharma Corp (NASDAQ:GEVA) last released its earnings data on Friday, May 2nd. The company reported ($1.16) earnings per share for the quarter, beating the analysts’ consensus estimate of ($1.19) by $0.03. Analysts expect that Synageva BioPharma Corp will post $-5.90 EPS for the current fiscal year.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.